ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)

Inclusion Criteria

• •Hospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression:
• •AIDS,
• •Aplastic anemia;
• •Asplenia;
• •Hematologic malignancy (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma);
• •Chemotherapy within the last 3 months;
• •Neutropenia defined as a white blood cell count less than 500/dL on a complete blood count;
• •Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;
• •Solid organ transplant;
• •Bone marrow transplant;
• •Chronic oral steroid use (\>10 mg/day prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose \> 600 mg prednisone);
• •Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \> 600 mg prednisone;
• •Active malignancy;
• •Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);
• •Lung malignancy with neutropenia/chemotherapy;
• •Other solid malignancy with neutropenia/chemotherapy;
• •Other immunodeficiency (including congenital/genetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);
• •Primary immunodeficiency.